FranΓ§aisπ See the interactive version (live chart) β
For Ameren, we replayed every analyst price target of the past 12 months and measured the real outcome: 27% were profitable, average return +4% (92 calls). At 3 months: +2% average return (36% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| BMO Capital | 18 | 28% | +11% |
| Wells Fargo | 16 | 31% | +3% |
| Morgan Stanley | 11 | 18% | -4% |
| B of A Securities | 8 | 12% | -1% |
| UBS | 7 | 43% | +16% |
Is Ameren overvalued, and is it a good time to buy Ameren right now? If you're wondering, here's a recap to make up your own mind: Ameren's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Ameren | Sector median (Utilities) |
|---|---|---|
| P/E | 19.0 | 20.9 |
| Forward P/E | 18.4 | 16.9 |
| Net margin | 19% | 14% |
π Ameren is valued in line with its sector (19.0 vs 20.9).
π P/E, PEG, marginβ¦: see the glossary
π΅ Dividend : Ameren pays about $2.92/share/yr β 2.60% yield. what is this?
The analyst consensus on Ameren (AEE) is "Buy" (18 bullish, 0 bearish calls over 12 months). This is not advice: historically, 27% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $120 (+12% vs $107), ranging from $114 to $137 (8 analysts).
Over 1 year, 27% of analyst targets on Ameren were profitable, for an average return of +4% (across 92 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $120 within 12 months, i.e. +12% vs the current price. The most bullish targets $137, the most cautious $114.
Note: analyst targets are 12-month (median $120, +12%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (27%), and the stock's past trajectory.
Its P/E is 19.0, forward P/E 18.4. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Ameren β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.